The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Pomalidomide Accord pomalidomide Generic | Accord Healthcare S.L.U. | Multiple Myeloma | 🇪🇺 EU 2024-07-26 | Order → |
| Apexelsin paclitaxel GenericAdditional monitoring | Whiteoak Pharmaceutical B.V. | Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2024-07-24 | Order → |
| Beqvez (previously Durveqtix) fidanacogene elaparvovec PRIMEATMPConditional | Pfizer Europe MA EEIG | Hemophilia B | 🇪🇺 EU 2024-07-24 | Order → |
| Cejemly sugemalimab Additional monitoring | Cstone Pharmaceuticals Ireland Limited | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2024-07-24 | Order → |
| Pomalidomide Krka pomalidomide Generic | KRKA tovarna zdravil d.d. Novo mesto | Multiple Myeloma | 🇪🇺 EU 2024-07-24 | Order → |
| Pomalidomide Zentiva pomalidomide Generic | Zentiva k.s. | Multiple Myeloma | 🇪🇺 EU 2024-07-24 | Order → |
| Zegalogue dasiglucagon Additional monitoring | Zealand Pharma A/S | Diabetes Mellitus | 🇪🇺 EU 2024-07-24 | Order → |
| Ixchiq Chikungunya vaccine (live) PRIMEAdditional monitoring | Valneva Austria GmbH | Chikungunya virus | 🇪🇺 EU 2024-06-28 | Order → |
| Eribulin Baxter eribulin Generic | Baxter Holding B.V. | Breast Neoplasms; Liposarcoma | 🇪🇺 EU 2024-06-27 | Order → |
| Obgemsa vibegron Additional monitoring | Pierre Fabre Medicament | Urinary Bladder, Overactive; Urinary Incontinence | 🇪🇺 EU 2024-06-27 | Order → |
| Fruzaqla fruquintinib Additional monitoring | Takeda Pharmaceuticals International AG Ireland | Colorectal Neoplasms | 🇪🇺 EU 2024-06-20 | Order → |
| Tosmova (previously Tocilizumab STADA and Tofidence) tocilizumab Biosimilar | STADA Arzneimittel AG | Arthritis, Rheumatoid; COVID-19 virus infection; Arthritis, Juvenile Rheumatoid | 🇪🇺 EU 2024-06-20 | Order → |
| Wezenla ustekinumab BiosimilarAdditional monitoring | Amgen Technology (Ireland) UC | Psoriasis; Arthritis, Psoriatic; Crohn Disease | 🇪🇺 EU 2024-06-20 | Order → |
| Altuvoct efanesoctocog alfa OrphanAdditional monitoring | Swedish Orphan Biovitrum AB (publ) | Hemophilia A | 🇪🇺 EU 2024-06-17 | Order → |
| Truqap capivasertib Additional monitoring | AstraZeneca AB | Breast Neoplasms | 🇪🇺 EU 2024-06-17 | Order → |
| Fluenz influenza vaccine (live attenuated, nasal) | AstraZeneca AB | Influenza, Human | 🇪🇺 EU 2024-06-03 | Order → |
| Agilus dantrolene sodium, hemiheptahydrate | Norgine B.V. | Malignant Hyperthermia | 🇪🇺 EU 2024-05-29 | Order → |
| Qalsody tofersen OrphanExceptional circumstancesAdditional monitoring | Biogen Netherlands B.V. | Amyotrophic Lateral Sclerosis | 🇪🇺 EU 2024-05-29 | Order → |
| Lytenava bevacizumab Additional monitoring | Outlook Therapeutics NL B. V. | Wet Macular Degeneration | 🇪🇺 EU 2024-05-27 | Order → |
| Neoatricon dopamine hydrochloride | BrePco Biopharma Limited | Hypotension | 🇪🇺 EU 2024-05-27 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.